SCHEMBL1628384

SCHEMBL1628384

Cc1ncc(C#N)c(N(C)S(C)(=O)=O)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 11/20 0.39
LRRK2 Q5S007 3/20 0.37
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PLK4 O00444 1/20 0.31
CHEK1 O14757 1/20 0.31
AURKA O14965 1/20 0.31
CHUK O15111 1/20 0.31
ROCK2 O75116 1/20 0.31
CHEK2 O96017 1/20 0.31
INSR P06213 1/20 0.31
CDK1 P06493 1/20 0.31
CSF1R P07333 1/20 0.31
PIM1 P11309 1/20 0.31
FGFR1 P11362 1/20 0.31
PRKACA P17612 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627151 0.76 ALDH1A1 (0.36) PTK2ALDH1A1HTT
SCHEMBL1626886 0.75 PTK2 (0.37) PTK2LRRK2ALDH1A1HTTKDM4E
SCHEMBL1625404 0.72 PTK2 (0.38) PTK2LRRK2ALDH1A1HTTTYK2
SCHEMBL12409799 0.72 PTK2 (0.44) PTK2
SCHEMBL21048910 0.71 PTK2 (0.40) PTK2LRRK2
SCHEMBL1628519 0.71 PTK2 (0.42) PTK2HPGD
SCHEMBL17258736 0.71 PTK2 (0.36) PTK2LRRK2ALDH1A1HTTKDM4E
SCHEMBL1230919 0.70 PTK2 (0.50) PTK2ALDH1A1HTTJAK3
SCHEMBL15434635 0.68 CSNK1A1 (0.39) ALDH1A1HTTKDM4EHPGDSMN1; SMN2
Acetic Acid SCHEMBL1626889 0.67 PTK2 (0.43) PTK2KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2025-07-03 US disclosed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 US disclosed
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2022-08-11 US disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
EP-2146779-B1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2016-08-10 EP disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 US disclosed
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH VERASTEM, INC. (US) 2015-03-19 US disclosed
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH LUZZIO MICHAEL JOSEPH (US) 2014-04-10 US disclosed
US-8440822-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. 2013-05-14 US disclosed
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER, INC. 2013-01-03 US disclosed
US-8247411-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2012-08-21 US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
EP-2146779-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2010-01-27 EP disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed
WO-2008129380-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885LRRK2 3997/4885ALDH1A1 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.